The EMBRACE Study The EMBRACE Study

Summary

Cardiomyopathy is a condition that affects the heart muscle, whereby it becomes enlarged, thick or rigid. When the heart muscle becomes involved, it affects the pumping action of the heart. This condition can affect as many as 10% of all patients after undergoing anthracycline cancer drug therapy and unfortunately carries the worst prognosis of all cardiomyopathies. To date, there is no effective intervention that will prevent a patient from developing this condition. The research conducted will look to see if an energy imbalance in the heart predates the onset of detrimental changes to the pumping function of the heart, if this is detected then we can act earlier to prevent the pumping function deteriorating.

Eligibility

Inclusion Criteria:

* A patient who has been diagnosed with breast cancer and has been scheduled for a first cycle of anthracycline therapy.
* Participant who is willing and able to give informed consent for participation in the study.
* Healthy (gender and age matched) volunteers willing to give informed consent for participation in the study.

Exclusion Criteria:

* Contraindication to magnetic resonance scanning such as an implantable cardiac device.

Conditions2

Browse More Trials